Cargando…

Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes

Detalles Bibliográficos
Autores principales:	Montarello, Natalie, Leslie, Alasdair, Chhetri, Rakchha, Friel, Oisin, Singhal, Deepak, Ross, David, Yeung, David, Kok, Chung H., Psaltis, Peter J., Hiwase, Devendra K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331405/ https://www.ncbi.nlm.nih.gov/pubmed/36884290 http://dx.doi.org/10.1182/bloodadvances.2022009173

Ejemplares similares

A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data
por: Sharplin, Kirsty, et al.
Publicado: (2023)

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome
por: Singhal, Deepak, et al.
Publicado: (2017)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study
por: Ho, P. Joy, et al.
Publicado: (2019)

Editorial: Risk-stratification in myelodysplastic syndromes
por: Breccia, Massimo, et al.
Publicado: (2022)

Risk stratification in therapy-related myelodysplastic syndromes
por: Zeidan, Amer M.
Publicado: (2017)

Management of patients with lower-risk myelodysplastic syndromes
por: Brunner, Andrew M., et al.
Publicado: (2022)

Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes
por: Awada, Hussein, et al.
Publicado: (2022)

Myelodysplastic syndromes: moving towards personalized management
por: Hellström-Lindberg, Eva, et al.
Publicado: (2020)

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2023)

EASIX for prediction of survival in lower-risk myelodysplastic syndromes
por: Merz, Almuth, et al.
Publicado: (2019)

Past, present and future in low-risk myelodysplastic syndrome
por: Toprak, Selami Kocak
Publicado: (2022)

Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome
por: Park, Songyi, et al.
Publicado: (2022)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
por: Saygin, Caner, et al.
Publicado: (2022)

Myelodysplastic syndromes
por: Hellström Lindberg, Eva
Publicado: (2018)

Utility of the p53 mutant protein in patients with low-risk myelodysplastic syndrome
por: Yao, David C., et al.
Publicado: (2014)

Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
por: Silva, Duarte Pacheco, et al.
Publicado: (2023)

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
por: Galili, Naomi, et al.
Publicado: (2012)

Part 5: Myelodysplastic syndromes—Treatment of high-risk disease
por: Magalhães, Silvia Maria Meira, et al.
Publicado: (2018)

Emerging treatment options for patients with high-risk myelodysplastic syndrome
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Angiogenesis in myelodysplastic syndromes
por: Pruneri, G, et al.
Publicado: (1999)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2023)

Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome
por: Merrill, Andrea L., et al.
Publicado: (2011)

Asthma and risk of myelodysplastic syndromes: a population-based cohort study
por: Frederiksen, Henrik, et al.
Publicado: (2017)

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes
por: Abáigar, María, et al.
Publicado: (2016)

Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification
por: Mahmood, Rafia, et al.
Publicado: (2018)

Abnormal Dendritic Cell-poiesis in Patients With Lower-risk Myelodysplastic Syndromes
por: Sánchez, Ángela, et al.
Publicado: (2020)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
por: Volpe, Virginia O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fqqpu22qedrknpg7utt1re5tf5